Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Stem Cells SpinWAR:SCS +0.42%38 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates WAR:SCS with a GF Score™ of 38/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,130 Biotechnology companies, Stem Cells Spin ranks worse than 88495.49% on this metric.
During the past 12 months, Stem Cells Spin's average EBITDA Per Share Growth Rate was 21.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -1.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Stem Cells Spin was 109.90% per year. The lowest was -23.20% per year. And the median was -5.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Stem Cells Spin 3-Year EBITDA Growth Rate Related Terms
WAR:SCS vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Stem Cells Spin's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Stem Cells Spin (WAR:SCS) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stem Cells Spin and its competitors. According to the industry distribution chart, Stem Cells Spin ranks #999999 out of 1130 companies in the Biotechnology industry.
Is Stem Cells Spin's 3-Year EBITDA Growth Rate too high?
Stem Cells Spin's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Stem Cells Spin ranks #999999 out of 1130 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #999999 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Stem Cells Spin in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Stem Cells Spin and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.48 — trading 380% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Stem Cells Spin's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.48 is trading 380% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: zł0.10 vs. price of zł0.48 (380% above fair value)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
38GF Score
Get the complete analysis for WAR:SCS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
